Compare · head to head
Incyte vs TriSalus Life Sciences
Incyte ranks higher overall — 360 rank 95 vs 62.
Incyte leads on Value (70 vs 46), Quality (68 vs 55) and Safety (68 vs 49). TriSalus Life Sciences leads on Sentiment (57 vs 44). The two are close on Growth.
Ranks as of 2026-06-12 · 1–100 vs true peers. Higher is better.
| Compare | ||
|---|---|---|
| Profile | ||
| Country | USA | USA |
| Sector | Health Care | Health Care |
| Industry | Biotechnology | Biotechnology |
| Size | Large | X-Small |
| ISIN | US45337C1027 | US89680M1018 |
| Last update | 2026-04-02 | 2026-04-02 |
| History | ||
| 360 (V1) since 2023 | ||
| Ranks | ||
| 360 | 95 | 62 |
| Value | 70 | 46 |
| Quality | 68 | 55 |
| Growth | 56 | 54 |
| Safety | 68 | 49 |
| Sentiment | 44 | 57 |
| Quality details | ||
| Profitability | 84 | 50 |
| Cash Truth | 51 | 60 |
Incyte vs Legend BiotechIncyte vs Seres TherapeuticsIncyte vs Kalvista PharmaceuticalsIncyte vs Syndax PharmaceuticalsAdd a third stock →
Full analyses: Incyte · TriSalus Life Sciences
Make Sense of the Ranks
Every rank runs 1–100 against true peers. Higher is always better.
360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100